National Graphite Corp.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NGRC research report →
About the company
National Graphite Corp. (NGRC), operating through its subsidiary Biotech Development Corp. , functions as a biopharmaceutical enterprise specializing in risk and cost-sharing models.
- CEO
- Mrs. Ulrike Dickmann
- IPO
- 2012
- Employees
- 1
- HQ
- Duesseldorf, DE
Price Chart
- Market Cap
- $4.47M
- P/E
- 72.50
- P/S
- 0.00
- P/B
- -2.04
- EV/EBITDA
- -132.61
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 4.99%
- ROIC
- 78.36%
- Revenue
- $0 · 0.00%
- Net Income
- $-56,963 · -7.00%
- EPS
- $0.00 · 0.00%
- Op Income
- $-49,733
- FCF YoY
- 0.00%
- 52W High
- $0.05
- 52W Low
- $0.02
- 50D MA
- $0.03
- 200D MA
- $0.03
- Beta
- -1.53
- Avg Volume
- 441
Get TickerSpark's AI analysis on NGRC
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our NGRC coverage
Recent articles, reports, and earnings notes.
No research on NGRC yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate NGRC report →Similar companies
Peers in the same neighborhood.